AbbVie (NY:ABBV)

263.82 +1.00 (+0.38%)

Delayed Quote Updated: 1:19 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

3 Dividend Stocks to Buy for Reliable Passive Income ↗

March 19, 2025

Via The Motley Fool

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients ↗

March 17, 2025

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data.

Via Benzinga

1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction ↗

March 16, 2025

Via The Motley Fool

Topics ETFs

Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025 ↗

March 14, 2025

Via The Motley Fool

Topics ETFs Stocks

AbbVie Options Trading: A Deep Dive into Market Sentiment ↗

March 07, 2025

Via Benzinga

13 Analysts Have This To Say About AbbVie ↗

March 04, 2025

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

March 04, 2025

Via Benzinga

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗

March 14, 2025

Via The Motley Fool

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗

March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Via Investor's Business Daily

Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever. ↗

March 12, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

March 11, 2025

Via Benzinga

Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? ↗

March 11, 2025

Vanguard has some excellent dividend ETFs, but they are right for different investors.

Via The Motley Fool

Topics ETFs

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

February 24, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas ↗

March 10, 2025

There's a lot going on for investors.

Via The Motley Fool

This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy? ↗

March 10, 2025

Via The Motley Fool

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week ↗

March 10, 2025

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

Via Stocktwits

3 Stocks Breaking Out Right Now ↗

March 09, 2025

These three stocks are touching new all-time highs.

Via Talk Markets

Topics Stocks / Equities

Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today? ↗

March 09, 2025

Via The Motley Fool

Topics ETFs Stocks

3 Cheap Stocks to Buy With Your Tax Refund Check ↗

March 07, 2025

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

March 07, 2025

Via The Motley Fool

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

March 04, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

Via StockStory

Topics Artificial Intelligence

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race ↗

March 03, 2025

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Via Benzinga

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗

March 03, 2025

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

Via Investor's Business Daily

These Vanguard ETFs Show Where the Smart Money Is Moving Now ↗

March 03, 2025

Via The Motley Fool

Topics ETFs

4 Sectors That Thrive When Inflation Runs Hot

February 28, 2025

Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value

Via MarketBeat

Topics Economy World Trade

3 Reasons ABBV is Risky and 1 Stock to Buy Instead

February 28, 2025

AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%.

Via StockStory

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

February 27, 2025

Via Benzinga

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

February 27, 2025

Via The Motley Fool

2 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗

February 23, 2025

With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income.

Via The Motley Fool

Topics ETFs

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.